PT3442977T - Inibidores do recetor de activina de tipo quinase - Google Patents
Inibidores do recetor de activina de tipo quinaseInfo
- Publication number
- PT3442977T PT3442977T PT177331089T PT17733108T PT3442977T PT 3442977 T PT3442977 T PT 3442977T PT 177331089 T PT177331089 T PT 177331089T PT 17733108 T PT17733108 T PT 17733108T PT 3442977 T PT3442977 T PT 3442977T
- Authority
- PT
- Portugal
- Prior art keywords
- kinase
- inhibitors
- activin receptor
- activin
- receptor
- Prior art date
Links
- 102000018918 Activin Receptors Human genes 0.000 title 1
- 108010052946 Activin Receptors Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322948P | 2016-04-15 | 2016-04-15 | |
| US201662411172P | 2016-10-21 | 2016-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3442977T true PT3442977T (pt) | 2023-10-04 |
Family
ID=59215888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177331089T PT3442977T (pt) | 2016-04-15 | 2017-04-14 | Inibidores do recetor de activina de tipo quinase |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US10233186B2 (pt) |
| EP (2) | EP3442977B1 (pt) |
| JP (1) | JP7017521B2 (pt) |
| KR (1) | KR102426043B1 (pt) |
| CN (1) | CN109311889B (pt) |
| AU (1) | AU2017250302B2 (pt) |
| CA (1) | CA3020870C (pt) |
| CL (1) | CL2018002945A1 (pt) |
| DK (1) | DK3442977T3 (pt) |
| ES (1) | ES2957233T3 (pt) |
| FI (1) | FI3442977T3 (pt) |
| HU (1) | HUE063042T2 (pt) |
| IL (1) | IL262345B (pt) |
| PH (1) | PH12018502205A1 (pt) |
| PL (1) | PL3442977T3 (pt) |
| PT (1) | PT3442977T (pt) |
| SG (1) | SG11201808907PA (pt) |
| WO (1) | WO2017181117A1 (pt) |
| ZA (2) | ZA201807256B (pt) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ703495A (en) | 2012-07-11 | 2018-02-23 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| JP6433974B2 (ja) | 2013-03-14 | 2018-12-05 | トレロ ファーマシューティカルズ， インコーポレイテッド | Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法 |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| LT3057969T (lt) | 2013-10-17 | 2018-07-10 | Blueprint Medicines Corporation | Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit |
| DK3395814T3 (da) | 2013-10-25 | 2022-07-04 | Blueprint Medicines Corp | Hæmmere af fibroblastvækstfaktorreceptoren |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| AU2016297754A1 (en) | 2015-07-24 | 2018-02-15 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to KIT and PDGFR |
| CA2995997A1 (en) | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| NZ742351A (en) | 2015-11-02 | 2023-03-31 | Blueprint Medicines Corp | Inhibitors of ret |
| MX2018006195A (es) | 2015-11-19 | 2018-09-05 | Blueprint Medicines Corp | Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk. |
| UY37155A (es) | 2016-03-17 | 2017-10-31 | Blueprint Medicines Corp | Inhibidores de ret |
| FI3442977T3 (fi) | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
| ES2793239T3 (es) | 2016-04-15 | 2020-11-13 | Abbvie Inc | Inhibidores del bromodominio |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| US11040979B2 (en) | 2017-03-31 | 2021-06-22 | Blueprint Medicines Corporation | Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR |
| WO2018195450A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| CN109081828B (zh) * | 2017-06-14 | 2021-03-26 | 上海时莱生物技术有限公司 | 聚(adp-核糖)聚合酶抑制剂、制备方法及用途 |
| EP3697786B1 (en) | 2017-10-18 | 2022-08-31 | Blueprint Medicines Corporation | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase |
| EP3773589B1 (en) | 2018-04-03 | 2023-11-01 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
| WO2020023910A1 (en) | 2018-07-26 | 2020-01-30 | Tolero Pharmaceuticals, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
| CA3117695A1 (en) | 2018-10-26 | 2020-04-30 | Keros Therapeutics, Inc. | Crystal forms of an alk2 inhibitor |
| CN109456253B (zh) * | 2019-01-11 | 2020-04-07 | 上海博璞诺科技发展有限公司 | 一种手性诱导合成(s)-3-(4-溴苯基)-哌啶或其盐的方法 |
| ES2966512T3 (es) | 2019-04-12 | 2024-04-22 | Blueprint Medicines Corp | Formas cristalinas de (S)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1H-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina y métodos de elaboración |
| CN114222745B (zh) * | 2019-08-13 | 2025-03-25 | 缆图药品公司 | 活化素受体样激酶抑制剂的盐和晶体形式 |
| JP2022549506A (ja) | 2019-09-27 | 2022-11-25 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症および関連状態を処置するための方法 |
| KR20260057225A (ko) | 2019-10-02 | 2026-04-27 | 블루프린트 메디신즈 코포레이션 | 액티빈 수용체-유사 키나제 억제제를 제조하는 방법 |
| CN110698388A (zh) * | 2019-11-01 | 2020-01-17 | 暨明医药科技（苏州）有限公司 | 一种工业化生产(s)-3-(4-溴苯基)哌啶的方法 |
| WO2021222875A1 (en) | 2020-04-30 | 2021-11-04 | Keros Therapeutics, Inc. | Methods of using alk2 inhibitors |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| CA3183728A1 (en) | 2020-05-29 | 2021-12-02 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| US20230235036A1 (en) * | 2020-06-05 | 2023-07-27 | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads | Acvr1 (alk2) receptor inhibition to treat neurological diseases |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| IL303812A (en) * | 2020-12-21 | 2023-08-01 | Biocryst Pharm Inc | Dosing regimens for oral ALK2 kinase inhibitors |
| JP7813290B2 (ja) * | 2021-01-07 | 2026-02-12 | バイオジェン・エムエイ・インコーポレイテッド | Ｔｙｋ２阻害剤 |
| JP2025525350A (ja) * | 2022-06-24 | 2025-08-05 | エフ． ホフマン－ラ ロシュ アーゲー | Ｍａｇｌ阻害剤としての新規複素環－カルボニル－環式化合物 |
| CN117800974A (zh) * | 2023-12-22 | 2024-04-02 | 西南科技大学 | 一种高能低感稠环含能化合物的制备方法 |
| GB202414353D0 (en) | 2024-09-30 | 2024-11-13 | Univ Nottingham | Multi-tissue organoid platform for developmental and disease modelling applications |
| CN118955554B (zh) * | 2024-10-15 | 2025-08-29 | 浙江瑞博制药有限公司 | 一种取代氧杂环化合物及其制备方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007519605A (ja) | 2004-01-30 | 2007-07-19 | 日本たばこ産業株式会社 | 食欲抑制薬 |
| US20120121540A1 (en) | 2007-08-10 | 2012-05-17 | Franz Ulrich Schmitz | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections |
| AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
| NZ596185A (en) * | 2009-04-16 | 2013-01-25 | Ct Nac Investigaciones Oncologicas Cnio | Imidazopyrazines for use as kinase inhibitors |
| AR077428A1 (es) | 2009-07-29 | 2011-08-24 | Sanofi Aventis | (aza) indolizinacarboxamidas ciclicas su preparacion y su uso como agentes farmaceuticos |
| NZ630719A (en) * | 2012-03-09 | 2017-01-27 | Lexicon Pharmaceuticals Inc | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof |
| KR102181318B1 (ko) | 2012-04-17 | 2020-11-20 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료를 위한 화합물 및 방법 |
| WO2013157022A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| NZ703495A (en) | 2012-07-11 | 2018-02-23 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| US20160115167A1 (en) * | 2013-03-04 | 2016-04-28 | The Brigham And Women's Hospital, Inc. | Bmp inhibitors and methods of use thereof |
| UY35419A (es) | 2013-03-14 | 2014-10-31 | Abbvie Inc | Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina |
| JP6433974B2 (ja) | 2013-03-14 | 2018-12-05 | トレロ ファーマシューティカルズ， インコーポレイテッド | Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法 |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| WO2014143241A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| LT3057969T (lt) | 2013-10-17 | 2018-07-10 | Blueprint Medicines Corporation | Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| DK3395814T3 (da) | 2013-10-25 | 2022-07-04 | Blueprint Medicines Corp | Hæmmere af fibroblastvækstfaktorreceptoren |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
| US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| JP2017523988A (ja) | 2014-08-05 | 2017-08-24 | アリオス バイオファーマ インク． | パラミクソウイルスを治療するための併用療法 |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| CA2982664A1 (en) | 2015-04-16 | 2016-10-20 | Merck Patent Gmbh | 3-(1h-benzimidazol-2-yl)-1h-pyridin-2-one derivatives |
| AU2016297754A1 (en) | 2015-07-24 | 2018-02-15 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to KIT and PDGFR |
| CA2995997A1 (en) | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| NZ742351A (en) | 2015-11-02 | 2023-03-31 | Blueprint Medicines Corp | Inhibitors of ret |
| MX2018006195A (es) | 2015-11-19 | 2018-09-05 | Blueprint Medicines Corp | Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk. |
| UY37155A (es) | 2016-03-17 | 2017-10-31 | Blueprint Medicines Corp | Inhibidores de ret |
| FI3442977T3 (fi) | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018049233A1 (en) | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
| EP3519402A1 (en) * | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| CN114222745B (zh) * | 2019-08-13 | 2025-03-25 | 缆图药品公司 | 活化素受体样激酶抑制剂的盐和晶体形式 |
-
2017
- 2017-04-14 FI FIEP17733108.9T patent/FI3442977T3/fi active
- 2017-04-14 CN CN201780035906.9A patent/CN109311889B/zh active Active
- 2017-04-14 AU AU2017250302A patent/AU2017250302B2/en active Active
- 2017-04-14 WO PCT/US2017/027775 patent/WO2017181117A1/en not_active Ceased
- 2017-04-14 SG SG11201808907PA patent/SG11201808907PA/en unknown
- 2017-04-14 ES ES17733108T patent/ES2957233T3/es active Active
- 2017-04-14 PL PL17733108.9T patent/PL3442977T3/pl unknown
- 2017-04-14 EP EP17733108.9A patent/EP3442977B1/en active Active
- 2017-04-14 KR KR1020187032927A patent/KR102426043B1/ko active Active
- 2017-04-14 PT PT177331089T patent/PT3442977T/pt unknown
- 2017-04-14 HU HUE17733108A patent/HUE063042T2/hu unknown
- 2017-04-14 JP JP2018553961A patent/JP7017521B2/ja active Active
- 2017-04-14 DK DK17733108.9T patent/DK3442977T3/da active
- 2017-04-14 EP EP23181727.1A patent/EP4285996A3/en not_active Withdrawn
- 2017-04-14 US US15/488,257 patent/US10233186B2/en active Active
- 2017-04-14 CA CA3020870A patent/CA3020870C/en active Active
-
2018
- 2018-10-14 IL IL262345A patent/IL262345B/en unknown
- 2018-10-15 PH PH12018502205A patent/PH12018502205A1/en unknown
- 2018-10-16 CL CL2018002945A patent/CL2018002945A1/es unknown
- 2018-10-30 ZA ZA2018/07256A patent/ZA201807256B/en unknown
-
2019
- 2019-03-05 US US16/293,317 patent/US10669277B2/en active Active
-
2020
- 2020-05-29 US US16/887,262 patent/US11634422B2/en active Active
- 2020-08-27 ZA ZA2020/05341A patent/ZA202005341B/en unknown
-
2023
- 2023-04-20 US US18/137,228 patent/US12595265B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202005341B (en) | Inhibitors of activin receptor-like kinase | |
| ZA201901034B (en) | Macrocycle kinase inhibitors | |
| IL268614A (en) | Aminotriazolopyridines as kinase inhibitors | |
| EP3273966A4 (en) | Inhibitors of cyclin-dependent kinases | |
| IL261606A (en) | Inhibitors of transfected menin-mll and methods of use | |
| SG11201608242XA (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| EP3347018A4 (en) | HEMMER OF CYCLINE-DEPENDENT KINASES | |
| PT3305788T (pt) | Inibidor da janus cinase | |
| IL257061A (en) | Inhibitors of ezh2 | |
| IL274207B (en) | Aminoimidazopyridazines as kinase inhibitors | |
| IL275457A (en) | Spiro exo-aza inhibitors of the MENIN-MLL interaction | |
| GB201615282D0 (en) | Tankyrase inhibitors | |
| ZA201701841B (en) | Macrocyclic lrrk2 kinase inhibitors | |
| EP3405477C0 (en) | TRANSGLUTAMINASE INHIBITORS | |
| GB201521059D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL258438B (en) | 2-Aminoquinoline derivatives as p70s6 kinase inhibitors | |
| GB201614783D0 (en) | Kinases inhibitors | |
| GB201519382D0 (en) | Kinase inhibitors | |
| GB201519381D0 (en) | Kinase inhibitors | |
| GB201404570D0 (en) | Macrocyclic kinase inhibitors | |
| GB201404555D0 (en) | Macrocyclic kinase inhibitors |